Alector Inc
NASDAQ:ALEC

Watchlist Manager
Alector Inc Logo
Alector Inc
NASDAQ:ALEC
Watchlist
Price: 1.52 USD 5.56% Market Closed
Market Cap: 152m USD

Operating Margin
Alector Inc

-165.3%
Current
-146%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-165.3%
=
Operating Profit
-146m
/
Revenue
88.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Alector Inc
NASDAQ:ALEC
152m USD
-165%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.2B USD
30%
US
Amgen Inc
NASDAQ:AMGN
159.7B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
138.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
118B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.3B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.4B USD
-5%

Alector Inc
Glance View

Market Cap
152m USD
Industry
Biotechnology

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

ALEC Intrinsic Value
6.39 USD
Undervaluation 76%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-165.3%
=
Operating Profit
-146m
/
Revenue
88.3m
What is the Operating Margin of Alector Inc?

Based on Alector Inc's most recent financial statements, the company has Operating Margin of -165.3%.

Back to Top